πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 15 of 18

  1. US 8771696

    Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor

    Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8765125

    Methods of treating autoimmune diseases with Dll4 antagonists

    Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8735095

    High affinity human antibodies to human IL-4 receptor

    Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8710004

    Stable liquid VEGF antagonist formulations

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8692052

    Genetically modified mice and engraftment

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8658853

    Low affinity FcΞ³R deficient mice

    Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8658154

    Humanized FcΞ³R mice

    Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8647842

    Methods for producing a fusion protein capable of binding VEGF

    Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8642741

    Human antibodies to human TNF-like ligand 1A (TL1A)

    Expires Mon Jan 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8637031

    Method of treating osteoarthritis with an antibody to NGF

    Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8613927

    High affinity human antibodies to human nerve growth factor

    Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8597898

    Fusion polypeptides capable of activating receptors

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8586713

    Readily isolated bispecific antibodies with native immunoglobulin format

    Expires Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8568721

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8545847

    Human antibodies to the human glucagon receptor and methods of use thereof

    Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8541646

    Genetically modified mice and engraftment

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8518887

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8501184

    High affinity human antibodies to PCSK9

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8481046

    VEGF antagonist formulations for intravitreal administration

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8470324

    Fusion polypeptides capable of activating receptors

    Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8445434

    IGF-1 fusion polypeptides and therapeutic uses thereof

    Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8425907

    Methods for treating pruritus by administering an antibody that specifically binds human PAR2

    Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8414876

    Methods of using IL-1 antagonists to treat autoinflammatory disease

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8414890

    Human antibodies to human RANKL, encoding nucleic acids and methods of treatment

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8404638

    Dimer VEGF antagonist formulations

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8388963

    Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8357371

    Methods for treating hypercholesterolemia using antibodies to PCSK9

    Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8354103

    Human antibodies to human angiopoietin-like protein 4

    Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8343737

    Cell culture compositions capable of producing a VEGF-binding fusion polypeptide

    Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8338135

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8337839

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8329181

    Methods for treating B-cell lymphoma by administering an anti-CD20 antibody

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8309088

    Method of treating osteoarthritis with an antibody to NGF

    Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8298532

    Fusion polypeptides capable of activating receptors

    Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8192741

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8183014

    High affinity antibodies to human IL-6 receptor

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8158581

    IGF-1 fusion polypeptides and therapeutic uses thereof

    Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8148107

    High affinity human antibodies to human nerve growth factor

    Expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8114394

    Use of IL-1 antagonists to treat gout

    Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8110546

    VEGF antagonist formulations

    Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8105805

    High affinity human antibodies to human IL-18 receptor

    Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8101724

    High-affinity human antibodies to human protease-activated receptor-2

    Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8097713

    Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof

    Expires Mon Jan 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8092803

    VEGF antagonist formulations for intravitreal administration

    Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8092802

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8084234

    Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF

    Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8080248

    Method of treating rheumatoid arthritis with an IL-6R antibody

    Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8075887

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Dec 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.